TG THERAPEUTICS, INC. (TGTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 250M 500M 750M FY16: 152K FY17: 152K FY18: 152K FY19: 152K FY20: 152K FY21: 6.7M FY22: 2.8M FY23: 233.7M FY24: 329M FY25: 616.3M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 200M 400M 600M FY21: 5.9M FY22: 2.5M FY23: 219.5M FY24: 290.5M FY25: 515.6M FY21 FY22 FY23 FY24 FY25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-450M -300M -150M 0 150M 300M 450M FY11: -882K FY12: -26.9M FY13: -23M FY14: -55.7M FY15: -63.2M FY16: -79M FY17: -118.7M FY18: -174.4M FY19: -169.1M FY20: -273.6M FY21: -344.8M FY22: -218.3M FY23: 20.6M FY24: 41.9M FY25: 123.3M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-400M -200M 0 200M 400M 600M FY01: -56.8K FY02: -1M FY03: -6M FY04: -5.9M FY05: -19.1M FY06: -9.7M FY07: -12M FY08: -4.3M FY09: -2.8M FY10: 623.6K FY11: -853.1K FY12: -18.1M FY13: -20.5M FY14: -55.8M FY15: -62.9M FY16: -78.3M FY17: -118.5M FY18: -173.5M FY19: -172.9M FY20: -279.4M FY21: -348.1M FY22: -223.8M FY23: 12.7M FY24: 23.4M FY25: 447.2M FY01 FY04 FY07 FY10 FY13 FY16 FY19 FY22 FY25

Cost of Revenue Annual

0 35M 70M 105M FY21: 790K FY22: 265K FY23: 14.1M FY24: 38.5M FY25: 100.7M FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-300M -150M 0 150M 300M 450M FY11: -86.6K FY12: -5.2M FY13: -10.7M FY14: -35.1M FY15: -44.7M FY16: -61.6M FY17: -93.8M FY18: -128.9M FY19: -132.8M FY20: -214.5M FY21: -295.6M FY22: -176.2M FY23: -31.4M FY24: -40.5M FY25: -24.8M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-300M -150M 0 150M 300M 450M FY11: -86.6K FY12: -5.2M FY13: -10.7M FY14: -35.1M FY15: -44.7M FY16: -61.9M FY17: -93.8M FY18: -129M FY19: -132.9M FY20: -214.9M FY21: -296M FY22: -176.2M FY23: -31.4M FY24: -40.6M FY25: -25M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 60M 120M 180M FY20: 115.3M FY21: 132.2M FY22: 135.4M FY23: 148.5M FY24: 160.3M FY25: 161.4M FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -2.00 -1.00 0.00 1.00 2.00 3.00 Q4 '11: -0.44 Q1 '12: -2.42 Q2 '12: -2.43 Q3 '12: -2.58 Q4 '13: -0.81 Q1 '14: -0.89 Q2 '14: -0.96 Q3 '14: -1.31 Q4 '14: -1.60 Q1 '15: -1.70 Q2 '15: -1.72 Q3 '15: -1.49 Q4 '15: -1.38 Q1 '16: -1.31 Q2 '16: -1.26 Q3 '16: -1.48 Q4 '16: -1.59 Q1 '17: -1.83 Q2 '17: -1.95 Q3 '17: -1.93 Q4 '17: -1.91 Q1 '18: -1.98 Q2 '18: -0.94 Q3 '18: -0.89 Q4 '18: -1.11 Q1 '19: -0.95 Q2 '19: -1.96 Q3 '19: -2.22 Q4 '19: -1.98 Q1 '20: -2.03 Q2 '20: -2.08 Q3 '20: -2.12 Q4 '20: -2.40 Q1 '21: -2.61 Q2 '21: -2.73 Q3 '21: -2.65 Q4 '21: -2.63 Q1 '22: -2.45 Q2 '22: -2.16 Q3 '22: -1.77 Q4 '22: -1.64 Q1 '23: -1.41 Q2 '23: -1.45 Q3 '23: -0.46 Q4 '23: 0.09 Q1 '24: 0.30 Q2 '24: 0.68 Q3 '24: -0.03 Q4 '24: 0.14 Q1 '25: 0.24 Q2 '25: 0.37 Q3 '25: 2.78 Q4 '25: 2.78 Q1 '26: 2.87 Q2 '26: 2.75 Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.